Next Article in Journal
Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches
Previous Article in Journal
Design and Evaluation of a Poly(Lactide-co-Glycolide)-Based In Situ Film-Forming System for Topical Delivery of Trolamine Salicylate
Previous Article in Special Issue
Augmentation of EPR Effect and Efficacy of Anticancer Nanomedicine by Carbon Monoxide Generating Agents
Article Menu

Article Versions

Export Article

Open AccessArticle

Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies

Chemical Materials Science and Nanochemistry Laboratory, Buketov Karaganda State University, 100026 Karaganda, Kazakhstan
Institute of Pharmaceutical Technology, Goethe University Frankfurt am Main, D-60438 Frankfurt am Main, Germany
I.M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(8), 410;
Received: 10 July 2019 / Revised: 31 July 2019 / Accepted: 8 August 2019 / Published: 12 August 2019
(This article belongs to the Special Issue Advanced Polymeric Delivery Systems for Cancer Therapy)
PDF [2463 KB, uploaded 12 August 2019]


Human serum albumin nanoparticles (HSA-NPs) have been widely used as drug delivery systems. In most cases, HSA-NPs are formed by the method of desolvation in the presence of glutaraldehyde as a crosslinking agent. In the present study, we showed the possibility of crosslinking human serum albumin (HSA) molecules with natural agents, urea, and cysteine at the nanoparticle level under mild conditions (at room temperature of 20–25 °C). Optimal concentrations of the interacting components (HSA, urea, and cysteine) were found to produce nanoparticles with optimal physico-chemical parameters (particle size, polydispersity, zeta potential, yield, etc.) for application as drug carriers. We used hydroxyurea (HU), a simple organic compound currently used as a cancer chemotherapeutic agent. The results indicated sizes of 196 ± 5 nm and 288 ± 10 nm with a surface charge of −22 ± 3.4 mV and −17.4 ± 0.5 mV for HSA-NPs (20 mg/mL of HSA, 0.01 mg/mL of cysteine, and 10 mg/mL of urea) and HSA–HU-NPs (2 mg/mL of HU), respectively. The yield of the HSA–HU-NPs was ~93% with an encapsulation efficiency of ~77%. Thus, the particles created (immobilized with HU) were stable over time and able to prolong the effect of the drug.
Keywords: human serum albumin; nanoparticles; hydroxyurea; cancer human serum albumin; nanoparticles; hydroxyurea; cancer

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Tazhbayev, Y.; Mukashev, O.; Burkeev, M.; Kreuter, J. Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies. Pharmaceutics 2019, 11, 410.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top